A Phase 1/2 interventional study of ALN-CC5 and Sterile Normal Saline (0.9% NaCl) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Alnylam Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom — 6 open to participants now, 12 under way, 6 of them phase 3. Hemoglobinuria, Paroxysmal · United Kingdom.
Among the 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom, this one is the 16th largest by enrollment of the 41 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 1/2, and was the 7th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →6 of the 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United Kingdom, Canada, Korea, Republic of
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in United Kingdom, Canada, France
Ages 12–17
Alexion Pharmaceuticals, Inc. · Sites in United Kingdom, United States, Australia and 4 more countries
Women only
ADARx Pharmaceuticals, Inc. · Sites in United Kingdom, Australia
Ages 18+ · Healthy volunteers
Regeneron Pharmaceuticals · Sites in United Kingdom, Brazil, Canada and 18 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 20 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2015.
This study's enrollment of 62 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 29 across the 41 interventional studies, 75 across the 4 observational. Of the 33 that completed or were terminated, 25 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 45 have an industry lead sponsor. The 10 most frequent:
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
Alnylam Pharmaceuticals has 1 study filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
4 of the studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT06449001Phase 3Alexion Pharmaceuticals, Inc.Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | 2027-05-28 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06298955Omeros CorporationLong-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ALN-CC5
Drug: Sterile Normal Saline (0.9% NaCl)
Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
calculated volume to match active comparator
Number of Participants With Adverse Events
Adverse events were reported for single-ascending doses (SAD) or multiple ascending doses (MAD) of ALN-CC5 when administered to healthy adult subjects and of multiple doses (MD) in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Time frame: Part A: through day 658; Part B: through day 532; Part C: through day 280
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Alternative Pathway (CAP)
Complement activity was measured in serum samples collected at timepoints throughout the study using the CAP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CAP from baseline.
Time frame: Part A: through day 70; Part B: through day 140; Part C: through day 140
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Classical Pathway (CCP)
Complement activity was measured in serum samples collected at time points throughout the study using the CCP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CCP from baseline.
Time frame: Part A: through day 70; Part B: through day 140; Part C: through day 140
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in C5 Protein Levels
Total C5 protein levels were measured in serum samples collected at time points throughout the study using a mass spectrometry-based method. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in C5 protein level from baseline.
Time frame: Part A: through day 70; Part B: through day 140; Part C: through day 140
Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (25-mer)
Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 25-mer.
Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (23-mer)
Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 23-mer.
Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Pharmacokinetic (PK) Effect of ALN-CC5: T Max (25-mer)
Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 25-mer.
Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Pharmacokinetic (PK) Effect of ALN-CC5: T Max (23-mer)
Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 23-mer.
Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (25-mer)
Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 25-mer.
Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (23-mer)
Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 23-mer.
Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
| Milestone | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 8 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 1 | 5 | 3 | 3 | 2 | 1 | 2 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
Adverse events were reported for single-ascending doses (SAD) or multiple ascending doses (MAD) of ALN-CC5 when administered to healthy adult subjects and of multiple doses (MD) in patients with paroxysmal nocturnal hemoglobinuria (PNH)
| Participants | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At least 1 Treatment Emergent Adverse Event (TEAE) | 6 | 0 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 6 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 |
| At least 1 Serious Adverse Event (SAE) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| At least 1 TEAE leading to discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Complement activity was measured in serum samples collected at timepoints throughout the study using the CAP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CAP from baseline.
| percentage reduction | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Alternative Pathway (CAP) | 18.823 ± 4.3020 | 49.321 ± 5.6718 | 26.337 ± 5.2159 | 64.435 ± 2.3138 | 47.628 ± 3.1740 | 58.525 ± 5.5782 | 72.517 ± 7.5442 | 58.914 ± 13.0568 | 66.097 ± 7.6113 | 25.419 ± 5.9153 | 63.224 ± 4.5313 | 78.028 ± 5.6692 | 70.618 ± 6.7831 | 68.367 ± 0.9750 | 77.079 ± 1.4564 | 76.470 ± 8.1563 | 25.951 ± 25.1389 | 77.558 ± 5.9434 |
Complement activity was measured in serum samples collected at time points throughout the study using the CCP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CCP from baseline.
| percentage reduction | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Classical Pathway (CCP) | 18.417 ± 2.7684 | 46.953 ± 2.8152 | 43.615 ± 6.0458 | 72.939 ± 3.4838 | 63.582 ± 2.5038 | 72.809 ± 1.5589 | 87.307 ± 1.3750 | 70.830 ± 11.7722 | 80.646 ± 4.2849 | 25.419 ± 6.2753 | 72.340 ± 3.4211 | 86.031 ± 4.1209 | 88.821 ± 6.3222 | 80.126 ± 1.6075 | 89.145 ± 1.9147 | 75.938 ± 7.2788 | 21.333 ± 20.2816 | 87.606 ± 4.9981 |
Total C5 protein levels were measured in serum samples collected at time points throughout the study using a mass spectrometry-based method. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in C5 protein level from baseline.
| percentage reduction | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in C5 Protein Levels | 15.88 ± 2.610 | 77.61 ± 3.249 | 73.44 ± 2.885 | 93.17 ± 0.898 | 88.62 ± 0.565 | 94.60 ± 1.378 | 97.62 ± 0.902 | 95.47 ± 0.306 | 97.49 ± 0.252 | 24.302 ± 5.9546 | 94.959 ± 0.6087 | 98.297 ± 0.4901 | 98.428 ± 0.2000 | 98.695 ± 0.1612 | 98.683 ± 0.3165 | 96.870 ± 1.8851 | 96.057 ± 1.3728 | 98.187 ± 0.2586 |
Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 25-mer.
| ng/mL | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (25-mer) | 14.4 ± 2.33 | 13.5 ± 4.38 | 69.8 ± 22.8 | 93.9 ± 30.8 | 111 ± 6.56 | 166 ± 42.7 | 217 ± 73.1 | 261 ± 79.5 | 21.0 ± 2.62 | 31.5 ± 7.64 | 81.2 ± 16.9 | 283 ± 17.0 | 61.7 ± 24.1 | 47.3 ± 16.4 | 74.1 ± 22.0 | — |
Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 23-mer.
| ng/mL | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (23-mer) | 27.2 ± 4.35 | 30.4 ± 4.21 | 144 ± 39.1 | 178 ± 38.1 | 384 ± 183 | 787 ± 473 | 710 ± 250 | 1500 ± 966 | 32.0 ± 15.4 | 44.7 ± 18.1 | 178 ± 17.9 | 1080 ± 243 | 167 ± 41.0 | 103 ± 8.48 | 242 ± 78.5 | — |
Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 25-mer.
| hr | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Effect of ALN-CC5: T Max (25-mer) | 0.50 (0.50 to 0.50) | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 0.50) | 0.50 (0.50 to 0.50) | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 0.50) | 1.00 (0.50 to 1.00) | 1.00 (1.00 to 1.00) | 1.0 (1.00 to 1.00) | 1.0 (1.00 to 1.00) | 0.75 (0.50 to 1.00) | 0.50 (0.50 to 1.00) | 1.00 (0.50 to 1.00) | 1.00 (0.5 to 1.50) | — |
Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 23-mer.
| hr | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Effect of ALN-CC5: T Max (23-mer) | 8.00 (6.00 to 12.00) | 8.00 (4.00 to 8.00) | 8.00 (8.00 to 8.02) | 6.00 (6.00 to 8.00) | 12.00 (4.00 to 12.02) | 4.00 (4.00 to 8.00) | 1.00 (0.50 to 12.00) | 6.00 (4.00 to 8.00) | 1.00 (1.00 to 1.00) | 1.00 (1.00 to 1.00) | 1.00 (1.00 to 1.00) | 7.00 (6.00 to 8.00) | 4.00 (0.50 to 12.00) | 8.00 (8.00 to 8.00) | 7.55 (5.93 to 9.17) | — |
Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 25-mer.
| h*ng/mL | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (25-mer) | 6.63 ± 3.71 | 7.50 ± 4.65 | 182 ± 101 | 198 ± 113 | 287 ± 67.2 | 574 ± 15.6 | 444 ± 78.2 | 757 ± 154 | 10.5 ± 1.31 | 15.8 ± 3.82 | 40.6 ± 8.44 | 843 ± 472 | 110 ± 11.6 | 93.5 ± 60.7 | 203 ± 51.0 | — |
Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 23-mer.
| h*ng/mL | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (23-mer) | 258 ± 58.6 | 277 ± 40.9 | 2290 ± 362 | 2470 ± 505 | 5450 ± 1630 | 10040 ± 3200 | 9720 ± 2260 | 21540 ± 9930 | 16.0 ± 7.71 | 22.3 ± 9.03 | 88.8 ± 8.95 | 14520 ± 2290 | 2420 ± 668 | 1700 ± 219 | 2930 ± 13.0 | — |
Collected over Part A: through day 658; Part B: through day 532; Part C: through day 280. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Single Ascending Dose | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| ALN-CC5 50mg - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| ALN-CC5 50mg (Japanese) - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 200mg - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| ALN-CC5 200mg (Japanese) - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| ALN-CC5 400mg - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 600mg - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 600mg (Japanese) - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| ALN-CC5 900mg - Single Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Placebo - Multiple Ascending Dose | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| ALN-CC5 100mg Weekly - Multiple Ascending Dose | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| ALN-CC5 200mg Weekly - Multiple Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 400mg Weekly - Multiple Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 600mg Biweekly - Multiple Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 Multiple Dose - Eculizumab Treated | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ALN-CC5 Multiple Dose - Eculizumab Naive | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/8 | 0/3 | 2/3 | 1/3 | 1/3 | 2/3 | 1/3 | 2/3 | 1/3 | 4/6 | 0/3 | 2/3 | 1/3 | 3/3 | 0/3 | 2/3 | 0/3 | 0/3 |
| Injection site painGeneral disorders | 0/8 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 |
| FatigueGeneral disorders | 0/8 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 2/3 | 1/3 |
| HeadacheNervous system disorders | 1/8 | 0/3 | 1/3 | 1/3 | 0/3 | 0/3 | 2/3 | 0/3 | 2/3 | 2/6 | 1/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 1/3 |
| NauseaGastrointestinal disorders | 2/8 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 2/3 | 0/3 | 0/3 | 1/6 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/3 | 1/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| ToothacheGastrointestinal disorders | 3/8 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Influenza like illnessGeneral disorders | 0/8 | 0/3 | 1/3 | 0/3 | 1/3 | 0/3 | 1/3 | 0/3 | 1/3 | 0/6 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Injection site rashGeneral disorders | 0/8 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Age, Categorical(Participants) | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 62 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 26 ± 5.0 | 24 ± 3.2 | 33 ± 7.0 | 22 ± 1.7 | 27 ± 5.0 | 23 ± 3.8 | 30 ± 6.7 | 30 ± 8.0 | 27 ± 5.6 | 27 ± 6.3 | 32 ± 7.6 | 29 ± 3.1 | 27 ± 2.9 | 29 ± 4.2 | 26 ± 3.8 | 23 ± 6.1 | 44 ± 16.9 | 44 ± 11.9 | 28.6 ± 8.12 |
| Sex: Female, Male(Participants) | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 0 | 1 | 1 | 3 | 0 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 24 |
| Male | 6 | 3 | 2 | 3 | 2 | 2 | 0 | 3 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 38 |
| Race (NIH/OMB)(Participants) | Placebo - Single Ascending Dose | ALN-CC5 50mg - Single Ascending Dose | ALN-CC5 50mg (Japanese) - Single Ascending Dose | ALN-CC5 200mg - Single Ascending Dose | ALN-CC5 200mg (Japanese) - Single Ascending Dose | ALN-CC5 400mg - Single Ascending Dose | ALN-CC5 600mg - Single Ascending Dose | ALN-CC5 600mg (Japanese) - Single Ascending Dose | ALN-CC5 900mg - Single Ascending Dose | Placebo - Multiple Ascending Dose | ALN-CC5 100mg Weekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly - Multiple Ascending Dose | ALN-CC5 400mg Weekly - Multiple Ascending Dose | ALN-CC5 600mg Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose | ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose | ALN-CC5 Multiple Dose - Eculizumab Treated | ALN-CC5 Multiple Dose - Eculizumab Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 | 0 | 3 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| White | 4 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 39 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2015, a primary completion of Apr 2016 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemdisiran